CTAD 2021: Scientific Posters Compilation November 17, 2021 Signant Health Posted in Scientific Advisory Share: LinkedIn0Tweet0 At the 14th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, hosted in Boston from November 9-12, 2021, Signant’s renowned Alzheimer’s disease experts and CNS thought leaders presented several scientific posters. Their original research explored a range of topics, including cultural influences on CDR and MMSE scores as well as the factors creating variances in screening and baseline scores. The posters reflect Signant’s deep therapeutic experience in Alzheimer’s disease, our powerful SmartSignals solutions, and our commitment to collaborative drug discovery and medical research innovation. Peruse the posters below and meet our CNS experts. Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics. Recent Posts Clinical Operations Prepare for These 4 Common Scale Management Challenges Sep 28, 2022 Karrie Crocco Learn more Scientific Advisory ISCTM 2022: Scientific Posters Compilation Sep 19, 2022 Signant Health Learn more Clinical Supplies Application Programming Interfaces (APIs) in Randomization and Trial Supply Management (RTSM) Aug 25, 2022 Susmita Petkar Learn more Scientific Advisory AAIC 2022: Scientific Posters Compilation Aug 19, 2022 Signant Health Learn more eCOA 5 Recommendations for Electronically Migrating and Implementing ClinROs Aug 10, 2022 Dan DeBonis Learn more
At the 14th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, hosted in Boston from November 9-12, 2021, Signant’s renowned Alzheimer’s disease experts and CNS thought leaders presented several scientific posters. Their original research explored a range of topics, including cultural influences on CDR and MMSE scores as well as the factors creating variances in screening and baseline scores. The posters reflect Signant’s deep therapeutic experience in Alzheimer’s disease, our powerful SmartSignals solutions, and our commitment to collaborative drug discovery and medical research innovation. Peruse the posters below and meet our CNS experts. Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.